Print Page    Close Window

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$9.88

 0.36 (3.52%)

High$10.23
Low$9.61
Volume72,761
Market Cap$104,993,130

09/22/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $9.88 with a 52 week high of $21.59 and a 52 week low of $7.20.

Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development

09/19/17

Read More

Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York

09/18/17

Read More

Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene

09/14/17

Read More

Gemphire Therapeutics, Inc. at Cantor Fitzgerald Global Healthcare Conference

09/26/17 8:00 a.m. ETView Event